Bio-Rad Laboratories IncBIO
Price$355.57Intrinsic value$224.0837% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $224.08median of 5 methods · middle span $141-$330based on filings through 30 Jun 2026
Market Price $355.57Price as of 1 Oct 2026
Margin of Safety -37.0%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 1.5% (near-term consensus, capped) · years 2–5: 4.9%/yr (balance of the path).4.2% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 64.5%Yr 74.2%Yr 83.8%Yr 93.4%Yr 103.0%
4.9% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)-11.6%
Discount rate (cost of equity) 9.6%
Volatility vs market (adjusted beta)1.03

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetBio-Rad Laboratories IncBIOHealth Care
Valuation
P/E43.3×
P/S4.0×
P/B1.4×
EV / Revenue4.1×
EV / EBITDA18.2×
Profitability
Gross margin51.9%
Operating margin1.8%
Net margin8.6%
FCF margin13.6%
Returns
ROE3.1%
ROA2.2%
ROIC3.0%
Growth
Revenue growth (YoY)0.9%
5-yr fwd EPS growth4.2%
Financial strength
Debt / Equity0.11×
Current ratio3.14×
Altman Z-Score3.6
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.